Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation.

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of ...

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Detailed price information for Xoma Royalty Corporation (XOMA-Q) from The Globe and Mail including charting and trades.

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.

Shares of Hillevax Inc (NASDAQ:HLVX) climbed 2.9% after the company revealed it had entered into a definitive merger ...